Official Operation of Hillgene R&D Center, Boosting the Innovation of the Biopharmaceutical Industry in Wuzhong District

This morning (June 28), the ribbon-cutting ceremony for the official operation of Spectrum Biotechnology R&D Center was held. Gu Hongjian, member of the Party Working Committee and deputy director of the Management Committee of Wuzhong Economic Development Zone, Shen Zhihua, director of the Wuzhong District Science and Technology Bureau, Yang Dongqin, general manager of Wuzhong Financial Holdings, relevant persons in charge of the District Industry and Information Technology Bureau, the main persons in charge of the Economic Development Zone Investment Promotion Bureau and Industrial Development Bureau, Li Hongjian, chairman of Jiangsu Spectrum Biotechnology Co., Ltd. and other senior executives attended the ribbon-cutting ceremony.

Photo: Gu Hongjian, member of the Party Working Committee and deputy director of the Management Committee of Wuzhong Economic and Technological Development Zone

This operation ceremony received great attention from the leaders. Mr. Gu Hongjian, member of the Party Working Committee and deputy director of the Management Committee of Wuzhong Economic and Technological Development Zone, delivered a speech and said: "'Paradise Suzhou · The Most Beautiful Wuzhong', Wuzhong Economic and Technological Development Zone is the main window of Wuzhong District's opening up to the outside world and the core sector of economic development. It focuses on planning and building many high-quality carriers such as Wuzhong Biopharmaceutical Industrial Park, and at the same time provides precise industrial policy support to create an industrial development ecosystem. The R&D center built by Spectrum Biotechnology with an investment of more than 30 million yuan covers an industrialization-oriented cell drug engineering technology R&D center and a cell drug quality testing center that supports the development of all-round analytical methods. It is another heavy layout for the industrialization problems that the cell drug industry urgently needs to solve. It not only shows Spectrum Biotechnology's long-term planning and blueprint in the industry, but also is another bright performance of Wuzhong Economic and Technological Development Zone. I hope that Spectrum Biotechnology will achieve more fruitful results in the fertile soil of the biopharmaceutical industry in the Economic and Technological Development Zone."

Figure: Ms. Jia Xiangjiao, Technical Director of Spectrum Biotechnology R&D Center

Ms. Jia Xiangjiao, Technical Director of Spectrum Biotechnology R&D Center, spoke on behalf of the employees and said: "I am very honored to join Spectrum Biotechnology. The R&D center was established under the personal planning and leadership of Dr. Zhu Yi, the company's CEO, and the planning of the R&D center was immediately started. Plan and build an industrialization-oriented cell drug engineering R&D center and a cell drug quality testing center that supports the development of all-round analytical methods. Targeting the fastest-growing emerging industries in the biopharmaceutical industry, such as CAR-T, TCR-T, UCAR-T, plasmid, lentivirus, iPS, MSC, mRNA, etc., we have made in-depth layouts, regardless of scale, equipment, process, technology, etc. We thank the leaders of Wuzhong District for their strong support for Spectrum Biotechnology and hope that the establishment of Spectrum Biotechnology R&D Center will contribute to the rapid development of the biopharmaceutical industry in Wuzhong District."

Photo: Mr. Li Hongjian, Chairman of Spectrum Biopharmaceuticals

Mr. Li Hongjian, Chairman of Spectrum Biopharmaceuticals, delivered a speech: "As of May 31, 2022, Spectrum Biopharmaceuticals has achieved a cumulative contract value of more than 400 million yuan, occupying the largest market share in China. Its industry status and influence are constantly increasing, and it has developed into a leading company in the domestic cell therapy CDMO segment.

Behind the numbers and achievements are the strong support and careful cultivation of leaders and departments at all levels in Wuzhong District and Economic Development Zone, from attracting investment to looking at sites, enterprise registration and landing, site relocation and construction to supporting brand launch activities, caring for the impact of the epidemic, from talent project application, Dong Wu led the talent and talent fund to the enterprise financing, especially the support of Wuzhong Financial Holdings, Suzhou Asset Management, and Wuzhong Rongyue Investment for the financing of Specxin Biotech. Everything and everyone that Specxin Biotech experienced in Suzhou, especially in Wuzhong Economic Development Zone, let us know that entrepreneurship is not lonely.

Specxin Biotech has the ability and confidence to provide high-quality full-process services to more innovative cell drug customers, bring more cell drugs to the market, benefit more patients, and realize the lofty vision of letting cell drugs write a new chapter in life! "

After the ceremony, leaders at all levels visited Specxin's GMP factory and R&D center. After the visit, the leaders expressed their recognition of Specxin's existing R&D and production capabilities, and hoped that Specxin Biotech would achieve further high-quality development in platform development, technological innovation, project implementation and other aspects in the future development process.